Warren Huff, Reata’s president and CEO, discussed the clinical progress of omaveloxolone and bardoxolone, as well as the company’s approach to drug development, before the stock surge in an exclusive interview with GEN Edge during the recent J.P. Morgan conference in San Francisco . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge